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DObjective: Dating back to the first published report of the Fontan circulation in 1971, multiple studies have
examined the long-term results of this standard procedure for palliation of single-ventricle heart disease in
children. Although the technique has evolved over the last 4 decades to include a polytetrafluorethylene
(PTFE) conduit for a large percentage of patients, the long-term outcome has not yet been established. The
aim of the current study was to investigate the possibility of a late increasing risk for death after 15 years among
patients with a modern Fontan operation and to evaluate late morbidity.
Methods: Between January 1, 1988, and December 31, 2011, 207 patients underwent the Fontan procedure
using an internal or external PTFE conduit plus a bidirectional cavopulmonary connection. Survival and late
adverse events were analyzed. Risk factors for early and late mortality were examined using hazard function
methodology.
Results: At 1, 10, and 20 years, survival for the entire cohort was 95%, 88%, and 76%, respectively, with no
deaths in the last 6 years of the study. Hazard modeling showed a 1.3% risk of death per year 24 years after the
Fontan procedure, with no late increasing hazard phase. Freedom from reoperations was greater than 90% at 20
years and freedom from thrombotic complications was 98% at 20 years (with greater than 80% of patients on
aspirin alone). Survival curves were superimposable for 16- to 20-mm conduits, and the freedom from any
reoperation including transplantation was greater than 90% after 20 years. Multivariable risk factor analysis
identified only earlier date of operation as a predictor of early and late mortality. By era of surgery, the
10-year predicated survival is 89% for patients undergoing surgery in 2000 and 94% for patients in 2010.
Conclusions: Early and late survival after a Fontan operation with a PTFE conduit is excellent, with no late
phase of increasing death risk after 20 years. Late functional status is good, the need for late reoperation is
rare, and thrombotic complications are uncommon on a standard medical regimen including aspirin as the
only anticoagulation medication. (J Thorac Cardiovasc Surg 2014;148:2517-24)See related commentary on page 2525.Supplemental material is available online.
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The Journal of Thoracic and Carthe perfect Fontan operation article by Fontan and
colleagues in 1990,1 a late phase of increasing hazard
has been postulated for these patients that predicts an
increasing risk of death or the need for transplant after the
first decade. We previously demonstrated the absence of a
late increasing risk of death during the first decade using
current surgical methods.2 The current analysis examines
late outcomes after 20 years using a standard surgical
technique.MATERIALS AND METHODS
Patient Population
Between January 1, 1988, and December 31, 2011, 207 patients at the
University of Alabama at Birmingham underwent a Fontan procedure using
an extracardiac or intracardiac polytetrafluoroethylene (PTFE) tube, with a
bidirectional cavopulmonary connection performed previously or during
the same procedure. The last Fontan procedure not using a tube occurred
in 1997; a PTFE tube has been used in all Fontan procedures since then.
The median age at operation was 4.6 years (range, 1.7-38 years). The
morphologic subsets are listed in Table 1. Although most patients managed
in a single ventricular pathway underwent a Fontan procedure, less than
20% of patients considered did not undergo a Fontan procedure because
of several risk factors including significant unrepairable atrioventricular
valve regurgitation, diminished ventricular function, and/or unfavorable
pulmonary artery anatomy.2diovascular Surgery c Volume 148, Number 6 2517
Abbreviations and Acronyms
NYHA ¼ New York Heart Association
PTFE ¼ polytetrafluorethylene
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DPatient Follow-up
The formal follow-up began on November 12, 2012. After obtaining
appropriate approval from our Institutional Review Board, attempts were
made to contact each of the 182 surviving patients using a standardized
interview form pertaining to general condition, adverse events, and New
York Heart Association (NYHA) class. All relevant medical records
were reviewed for operative, follow-up, and adverse event information.
After 3 failed attempts to contact each patient, the last documentedmedical
encounter at the University of Alabama at Birmingham or elsewhere was
used to obtain follow-up and adverse event information. Patients were
censored at the time of last follow-up, and no patient was assumed to be
alive past that point of documentation. The follow-up completeness index
was 89%. Follow-up was formally completed on February 28, 2013.
Among all surviving patients, the median follow-up was 5.4 years, with
a maximum of 22.8 years. The study period divided by era included 112
patients from 1988 to 2005 and 95 patients from 2006 to 2011.
Adverse Events
Documented arrhythmia was defined as any documented treatment of a
disturbance of rhythm after initial hospitalization and/or recollection of
such treatment by family members during a telephone interview.
Reoperations, including Fontan takedown, Fontan revision, cardiac
transplantation, and additional cardiac procedures, were documented for
each patient.
Thrombosis and thromboembolism included 2 subsets: first, any cardiac
or extracardiac thromboembolic episode documented during follow-up;
second, any episode of thrombosis within the PTFE tube or the Fontan
pathway. All patients were routinely discharged on aspirin as the only
anticoagulant unless there was a prior history of thromboembolic episodes,
in which case warfarin was added. The addition of warfarin at the time of
hospital discharge or during follow-up was documented for each patient.
Surgical Strategy
All patients were operated on through a median sternotomy using
cardiopulmonary bypass with moderate hypothermia. All patients
underwent a bidirectional cavopulmonary connection as part of the final
reconstruction. Of the 207 patients, 164 (79%) received the cavopulmo-
nary connection at a previous operation. All fenestrations, when performed,
were accomplished with a 4-mm punched hole in the PTFE tube.
Statistical Analysis
Nonparametric estimates of freedom from event and survival were
obtained using the Kaplan-Meier method. P values for stratified non-
parametric comparisons were determined using the log-rank test.
Parametric estimates of freedom from death after completion of the
Fontan procedure using PTFE tubes were obtained usingmultiphase hazard
analysis in which the instantaneous risk (hazard) of death was estimated as
a function of time.3 Parametric hazard analysis allows estimation of the
instantaneous risk at each moment in time starting with time zero, which,
for this study, was the time the Fontan procedure was performed. The
3-phase hazard analysis identifies up to 3 separate but overlapping phases
of hazard. The effect of risk factors is estimated by proportional hazards
regression within each phase of hazard. To estimate the risk, we calculated
LðtÞ ¼ u1g1ðt; xÞþu2g2ðt; xÞ ¼ u3g3ðt; xÞ
where each u is a log-linear function of the hazard phase; g1, g2, and g3 are
shaping functions; t is the time to event; and x represents the risk factors.2518 The Journal of Thoracic and Cardiovascular SurSpecific analyses examined the possible presence of an early, constant,
and late increasing phase of risk with associated risk factors. The variables
included in the multivariable analysis are listed in Appendix E1.
All statistics were performed using SAS software version 9.3
(SAS Institute, Inc, Cary, NC) in conjunction with custom software
used for hazard analysis (for additional details, see http://www.
clevelandclinic.org/heartcenter/hazard).
RESULTS
Evolution of the Fontan Technique
During this 24-year experience, a preliminary bidirec-
tional cavopulmonary connection has been used almost
exclusively since 1992. In the initial part of the experience,
an internal PTFE (n ¼ 61) tube was used to connect the
inferior vena cava to the pulmonary arteries. External tube
placement began in 1998 and since 2001 has been the
uniform method of Fontan construction.
Survival
The 1-, 10-, and 20-year survival with the use of a PTFE
tube was 95%, 88%, and 77%, respectively (Figure 1). A
rapidly declining early risk phase merged with a constant
phase at about 1 month. No late increasing phase of risk
was identified after 20 years. The constant phase hazard
function was calculated at 1.3%/y over the study period.
Hospital mortality decreased from 7% between 1988
and 1997 to 0% since 2005. Patients receiving a
Fontan procedure in the earlier era (1988-1997) had inferior
10-year survival compared with the recent era (1998-2011)
(80% vs 92%, P ¼ .009) (Figure 2). Causes of death are
listed in Table 2.
Size and Location of the PTFE Tube
Most patients (146 of 207; 70%) received an extracardiac
tube, and 82% (169 of 207) of tubes were 16 mm in
diameter (Table 3). Survival stratified by tube size
(Figure 3) suggests optimal survival with a PTFE tube of
16 mm or larger.
Fenestration
A fenestration was performed at the time of the Fontan
procedure in 94 of 207 (45%) patients. Fenestration at the
time of Fontan procedure was not associated with improved
long-term survival (P¼ .2). At the time of last follow-up, 28
of 74 (38%) patients with complete data still had a fenestra-
tion. A total of 24 (32%) patients underwent fenestration
closure; 22 (30%) patients had spontaneous closure.
Reoperations After the Fontan Procedure
A total of 15 reoperations were performed (Table 4).
Freedom from any reoperation, including transplantation,
was greater than 90% after 20 years for patients receiving
a PTFE tube of 16 mm or larger (Figure 4). The Fontan
revisions included 1 patient who required connection of
an aberrant hepatic vein to the Fontan pathway, 2 patientsgery c December 2014
FIGURE 2. Actuarial survival after Fontan procedure, stratified by era of
operations. Error bars represent 1SE. UAB, University of Alabama at
Birmingham; PTFE, polytetrafluoroethylene.
TABLE 1. Cardiac morphology
Morphology n %
Tricuspid atresia 59 29
Double inlet left ventricle 25 12
Hypoplastic left heart syndrome 18 9
Complex double outlet right ventricle 17 8
Heterotaxy/discordant atrioventricular connections 12 6
Unbalanced atrioventricular septal defect 12 6
Pulmonary atresia/intact ventricular septum 11 5
Other single ventricle 43 21
Other complex congenital cardiac disease 10 5
Total 207 100
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Dwho required replacement of conduits from the hepatic
veins to the pulmonary artery, 1 patient with conduit throm-
bosis whose conduit was relocated to the main pulmonary
artery, and 1 patient who underwent division of the main
pulmonary artery. The type of revision was unknown for 1
patient.
Thromboembolic Events
The standard protocol during this experience incorpo-
rated aspirin alone for anticoagulation (Table 5). Warfarin
was added if specific indications existed. At last
follow-up, 81% of patients were taking aspirin as the
only anticoagulation medication (Table 6). The actuarial
freedom from any thrombotic or thromboembolic event
was 98% for each at 20 years.
Arrhythmias
The risk of arrhythmia (see Materials and Methods
section for definition) was less with extracardiac tube
placement (Figure 5). Freedom from documentedFIGURE 1. Actuarial and parametric survival after the Fontan operation
using polytetrafluoroethylene (PTFE) tubes, the lower red line indicates
the instantaneous risk (hazard) of death, in which the rapidly falling early
phase merges with a constant phasewithin the first 3 months. The error bars
represent 1SE. The dashed lines enclose the 70% confidence limits.
UAB, University of Alabama at Birmingham.
The Journal of Thoracic and Carsupraventricular arrhythmias was 73% at 10 years in the ex-
tracardiac PTFE group, and for any arrhythmia 71%. Pace-
maker implantation was required in 10 patients, 5 with
external tubes and 5 with internal tubes.
Functional State
Most surviving patients were in NYHA class I or II at
follow-up, even beyond 12 years (Figure 6). Less than
10% of patients were either in NYHA class III or unknown.
By logistic regression, time since Fontan did not affect
NYHA class (P ¼ .96).
Risk Factor Analysis
By multivariable analysis, earlier date of operation was
the only risk factor identified in the early (P ¼ .04) and
constant (P ¼ .02) phases. The effect was most evident
during the 1990s decade, and the effect of operative date
was absent after 1998. Solution of the multivariable
equation indicated an expected 10-year survival of 94%
for a patient receiving the Fontan operation in 2010
(Figure 7).
DISCUSSION
Evolution of the Fontan Operation
The Fontan operation has undergone significant evolu-
tion since its inception4 and since the classic analysis ofTABLE 2. Causes of death
Cause of death n %
Early failed Fontan 8 32
Late failed Fontan 8 32
Cardiac arrest 1 4
Endocarditis 1 4
Stroke 1 4
Unknown 6 24
Total 25 100
diovascular Surgery c Volume 148, Number 6 2519
TABLE 3. Tube sizes
PTFE tube size (mm) Intracardiac (n) Extracardiac (n) Total
13 0 1 1
14 4 2 6
16 57 112 169
18 0 13 13
19 0 14 14
20 0 4 4
Total 61 146 207
PTFE, Polytetrafluoroethylene.
TABLE 4. Reoperations after the Fontan
Reoperations n
Fontan takedown 5
Fontan revision 6
Heart transplant 1
Resection of left ventricular outflow tract obstruction 1
Tricuspid replacement 1
Closure of aberrant hepatic vein 1
Total 15
Congenital Heart Disease Dabal et al
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Dthe perfect Fontan.1 During that era, common surgical
options included right atrial appendage to a divided
main pulmonary artery,5 right atrial appendage to right ven-
tricular outflow tract (Bjork modification),6 and direct
connection between the roof of the right atrium and the right
pulmonary artery. The lateral tunnel was introduced later.7
The extracardiac conduit with disconnection of the inferior
vena cava was described by Humes and Danielson8 and
suggested as the technique of choice for all Fontan opera-
tions by Marcelletti.9 With the emphasis on streamlining
blood flow through the Fontan pathway by DeLeval and
others,10 we evolved to a practice of routine use of a
PTFE tube by 1990. This evolution to a standardized
technique led to the routine achievement of the perfect
Fontan pathway based on our 2008 analysis.2Survival
The 1990 Fontan analysis of the perfect Fontan predicted
a 15-year survival of 73%1 during an era in which a variety
of surgical techniques were used. The improved survival
with the PTFE tube technique provided 10-year survivals
of 88% to 90%.2,11 The current analysis indicatesFIGURE 3. Actuarial survival after Fontan procedure, stratified by tube
size. UAB, University of Alabama at Birmingham; PTFE, polytetrafluoro-
ethylene.
2520 The Journal of Thoracic and Cardiovascular Surongoing improvement in survival over time, even among
patients receiving an extracardiac tube. In the current era
of pediatric cardiac surgery with improved management
of patients after Fontan surgery, the projected survival for
patients undergoing the extracardiac tube Fontan
procedure has improved to 94% for a patient operated on
in 2010. The current analysis suggests that an intracardiac
Fontan procedure may be a better surgical option than a
higher risk ventricular repair in certain patients whose
repair includes considerable imponderables.Tube Size and Location
The opportunity to further simplify the operation by
avoiding cardiac ischemia was a stimulus to evolve from
intracardiac to extracardiac tubes, which includes the
option for implantation without cardiopulmonary bypass.11
Appropriate tube size remains a controversial issue.
Although some have argued that a PTFE tube of 20 mm
or greater is needed to allow for patient growth,12 our
experience suggests that a 16-mm PTFE tube is adequate
for the adult size patient. Furthermore, Itatani and
colleagues13 have demonstrated superior flow characteris-
tics with tubes of 16 or 18 mm.FIGURE 4. Freedom from reoperation, stratified by tube size. UAB,
University of Alabama at Birmingham; PTFE, polytetrafluoroethylene;
HTx, heart transplantation.
gery c December 2014
TABLE 5. Anticoagulation medications at discharge
Anticoagulation medications n %
None 10 5
Aspirin only 165 82
Coumadin only 9 4
Aspirin and warfarin 14 7
Other (dabigatran etexilate) 1 <1
Unknown 3 1
Total 202 100
FIGURE 5. Freedom from arrhythmias, stratified by internal versus
external PTFE tube. UAB, University of Alabama at Birmingham;
PTFE, polytetrafluoroethylene.
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In this experience, fenestration of the Fontan pathway
was not used routinely, but rather selectively for patients
perceived to be at higher risk of increased Fontan pathway
pressures including patients with unfavorable pulmonary
artery anatomy, those with significant atrioventricular valve
regurgitation, and those with diminished function. Fenestra-
tions were routinely accomplished with a 4-mm punch,
although some have recommended a 5-mm hole for patients
more than about 12 kg.14 Fenestration did not confer a
demonstrable survival advantage, but we cannot exclude
the possibility that a fenestration may neutralize certain
risk factors for early morbidity.15 Although controversy
exists on the value of fenestration,16,17 recent practice
reports indicate that fenestration is used in more than
50% of Fontan procedures in the United States.16Reoperations
Late reoperations have been rare in this experience in
whichmost patients received a 16-mm tube. In an era before
the use of PTFE conduits, the risk of requiring reoperation
for pathway obstruction gradually increased over time. This
has not been the case with the use of PTFE tubes, in which
late conduit obstruction is rare,11,17-20 and no late increasing
hazard was identified in this experience after 20 years.Thromboembolic Event
Thromboembolic complications before the recent erawere
reported among 5% to 16% of patients,24,26 often in the
setting of stasis of flow in a markedly dilated right atrium.
Possibly related to maintenance of laminar flow and
reduced stasis with the extracardiac conduit and lateralTABLE 6. Anticoagulation medications at follow-up
Anticoagulation medications n %
None 22 12
Aspirin only 148 81
Warfarin only 6 3
Aspirin and warfarin 3 2
Subcutaneous heparin 1 <1
Unknown 2 1
Total 182 100
The Journal of Thoracic and Cartunnel approaches, this experience and others indicate a
very low risk of thrombosis late after an extracardiac
conduit Fontan procedure.2,11 The level of anticoagulation
required to minimize thrombosis remains controversial,
particularly the need for routine warfarin administration.
This experience and our previous analysis2 support the
routine use of aspirin, reserving warfarin for patients with
documented risk factors for thromboembolic events.
Rhythm Disturbances
In this experience, supraventricular and overall rhythm
disturbances were less common in patients receiving
extracardiac versus intracardiac conduits. The advantages
of avoiding a long atrial suture line is supported by
clinical11,27 and experimental28,29 studies, which show
greater preservation of sinus rhythm and lower incidence
of supraventricular arrhythmias with an extracardiac tube
versus the lateral tunnel.
Functional State
Before the construction of streamlined pathways,
functional status was noted to gradually decline over
time.2 In this experience, the proportion of patients in
NYHA class I has remained quite stable for a 15-year
interval from the time of surgery; 100 patients have reached
that interval. In addition, almost patients regardless of
interval of follow-up remain highly functional. Others
have reported that patients with lateral tunnel or extracar-
diac conduits (see Results section) have better functional
outcomes than with previous Fontan techniques, but
exercise capacity remains well below normal.21-23 At least
1 multicenter study suggests better functional outcomes
with extracardiac conduits compared with a lateral
tunnel.24 It has been hypothesized that improved late
functional outcomes relate to more preserved ventriculardiovascular Surgery c Volume 148, Number 6 2521
FIGURE 6. Percentage of patients in specified NYHA classes at the indicated follow-up intervals after the Fontan operation. UAB, University of Alabama
at Birmingham; PTFE, polytetrafluoroethylene; NYHA, New York Heart Association.
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Dfunction caused by the absence of increased coronary
sinus pressure (by draining the coronary sinus into the
low-pressure atrium) and avoidance of myocardial ischemia
during the repair.25Limitations
The current study is limited primarily because it repre-
sents experience in a single institution and is retrospective
in nature. The patient population, although encompassingFIGURE 7. Nomogram of a solution to the multivariable risk factor
equation for survival after Fontan. Solutions are depicted for Fontan
procedures performed in 1990, 2000, and 2010. Dashed lines enclose the
90% confidence limits. UAB, University of Alabama at Birmingham;
PTFE, polytetrafluoroethylene.
2522 The Journal of Thoracic and Cardiovascular Surall common single-ventricle conditions, is somewhat biased
because of a relatively small percentage of patients with a
hypoplastic left heart, who are only represented in the last
decade of the experience. Patients with hypoplastic left
heart syndrome were underrepresented in the study
population because Norwood procedures were not
performed at the study institution until the later in the study
period. Future analysis of this cohort with longer follow-up
will be necessary and will include a larger percentage of
patients with hypoplastic left heart syndrome. The current
literature, however, is mixed with regard to the effect of
single ventricular morphology on Fontan outcomes
although several studies suggest that outcomes with
systemic right ventricles are equivalent to systemic left
ventricles.14,16 Although the current study does not show
a late increasing hazard after 20 years, further follow-up
may lead to the characterization of such a phase beyond
25 years or more.CONCLUSIONS
A standardized Fontan operation using a 16-mm or
greater extracardiac conduit and a bidirectional cavo-
pulmonary connection offers excellent long-term survival,
freedom from reoperation, and good functional state. For
the first time, the absence of a late increasing phase of
risk has been documented after at least 20 years.References
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Dr Harold M. Burkhart (Oklahoma City, Okla). Dr Dabal and
colleagues from the University of Alabama continue their quest for
the perfect Fontan in their most recent series update. They present
a 25-year Fontan experience involving more than 200 patients with
excellent survival and an extremely low risk of reoperation. Of
note, they demonstrate no increasing phase of risk after 20 years.
Congratulations on the excellent results and the very nice
presentation.
I have 3 questions.
First, we all know that picking the perfect patient is the first step
to a perfect Fontan result. Could you please discuss your current
exclusion criteria for offering a Fontan operation; specifically,
where do atrioventricular valve regurgitation, ventricular dysfunc-
tion, and marginal pulmonary architecture fit in? What percentage
of your patients initially planned for the Fontan pathways are
ultimately denied the operation?
Dr Dabal. Thank you for your comments and thank you for
your questions. The first question is an excellent one. If you
look at our series and you look at the last publication from our
institution on our Fontan results, the percentage of patients that
do not ultimately end up with a Fontan palliation who initially
begin on that pathway is in the neighborhood of 15%. And I think
that you have mentioned the main reasons why patients do not
make it: decreased cardiac function; unfavorable pulmonary
vasculature or high pulmonary artery pressures; significant
atrioventricular valve regurgitation. Those are probably the 3
biggest factors that would preclude us from performing a Fontan.
Dr Burkhart.My second question is along the same lines as the
first question. I note, as you noted, 10% of your patients, or less
than, had hypoplastic left heart syndrome and they have a lot of
the problems that we discussed earlier in the exclusion
criteria. Given that most large series typically have a higher
proportion, could you first explain why yours does not have that
proportion; and furthermore, do you think that if you did have
that proportion your results would be different?
Dr Dabal. So the hypoplastic population is definitely only
represented in the latter part of our experience. Until about
2005, those patients were not having Norwoods in Alabama, so
that is why they are somewhat underrepresented in the population.
Based on our multivariable analysis, however, morphology did
not make any difference in survival. It was not a risk factor for
mortality. I think that certainly as we get increasing length of
follow-up this may change, but I think that there are plenty of
data out there to suggest from multiple institutions that ventricular
morphology is not necessarily a risk factor for poor late-term
outcomes.diovascular Surgery c Volume 148, Number 6 2523
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DDr Burkhart. And my final question is a technical one. I note
that the average age of Fontan in your group is almost 5 years;
however, the most common conduit size is 16 mm. As you
know, some have argued for larger conduits especially in larger pa-
tients. Would you please discuss your current approach to and
reasoning behind your conduit choice.
Dr Dabal. Well, I think that the conduit choice has been a
personal preference, but it is borne out by the literature. If you
look at a lot of the computational analyses of flow characteristics
of 16-mm tubes, it has been shown that those are preferable to
larger tubes in terms of lower risk of stasis and risk of thrombosis
related to that stasis. I think that our experience has been somewhat
skewed by the era effect. If you look at the latter era, our median
age of operation is probably significantly lower than 4.6 years,
probably closer to the 2- to 3-year age range. And the bottom
line is a 16-mm conduit is almost always easily put into a child
at that size. Our long-term results have shown that it really does
not make much difference, that the results are as good or better
with a 16-mm tube as they are with an 18- or 20-mm tube, and
so that is our logic for doing that.
Dr Sertac M. Cicek (Istanbul, Turkey). Congratulations on the
excellent results. You stated that almost 50% of the patients
had a fenestration, 45% exactly. What are your indications for
fenestration? This is a significantly high incidence of fenestration
for such a group of patients.
Dr Dabal. Thank you for the question. I think that that is
another factor that has changed significantly over the experience
at the University of Alabama at Birmingham. Earlier in the
experience there was routine fenestration for most patients;
however, over the last 5 to 10 years we have been much more
selective with our application of fenestrations. Currently, our
indications are similar to what we would consider to be high-risk
Fontans. So any patient who has decreased function, a significant
amount of atrioventricular valve regurgitation, or unfavorable
pulmonary artery anatomy, those are the 3 categories of patients
that we would consider fenestrating.
Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). When
you performed your era analysis, what was the decision
making for the year that you chose to separate the 2 groups
into the 2 eras?
Dr Dabal. I think we basically split it down the middle.
Dr Hirsch-Romano. Was there a change in surgical technique
or management strategy at that time?
Dr Dabal. No, there really was not. The only significant
change during the period was the transition from intracardiac to2524 The Journal of Thoracic and Cardiovascular Surextracardiac tubes, but there was no change really in the middle
or latter part of the study period.
Dr Hillel Laks (Los Angeles, Calif). I enjoyed your talk very
much. I would just caution about the 16-mm graft. In our
experience we have had 1 reoperation for a 16-mm graft and this
was in a female who was quite tall. It occurred when she was
adult size, about 1.7 m tall. But this was a patient who had a
fenestration that was subsequently closed with an Amplatzer
device, and potentially the addition of some added encroachment
on the lumen made a difference; she had about a 5-mm gradient
across it. So I would say that we now prefer always using an
18-mm or a 20-mm graft wherever possible. But in younger
children, sometimes it is difficult to get a 16-mm graft into a
3-year-old who is small; in that case it may be worthwhile waiting
longer until the child is bigger, and particularly if it is a boy with
large parents and you are expecting that child to become quite
large. I think that a 16-mm graft in a full-size adult with a big
body surface area is going to be inadequate and it is worthwhile
trying to put a larger graft in.
Dr Dabal. Thank you for your comment.
Dr Carl L. Backer (Chicago, Ill). Apropos the presentations
here on Saturday morning where we discussed extracardiac Fontan
versus lateral tunnel; it seems that your paper is a very nice
addition to the literature supporting extracardiac Fontan. I want
to take the opportunity to survey this very august group. How
many surgeons primarily use the extracardiac Fontan approach
when they do a Fontan operation?
(Show of hands.)
All right. How many surgeons use the lateral tunnel?
(Show of hands.)
It looks like you have now convinced a few more surgeons.
For the primary Fontan, it looked to me that about 80% of
surgeons are doing extracardiac and 20% are doing the lateral
tunnel.
The second thing I noticed in your study was that 81% of
your patients are on aspirin, which has been our institutional
strategy. I would like to survey this group; how many are
keeping their patients solely on aspirin after the Fontan operation?
(Show of hands.)
It looks like a pretty sizable number of hands.
And how many are on warfarin?
(Show of hands.)
My read on this is that about 70% of people are putting their
patient on aspirin after a Fontan operation and maybe 25% to
30% on warfarin.gery c December 2014
APPENDIX E1. VARIABLES ENTERED IN THE
MULTIVARIABLE RISK MODEL FOR DEATH
Age at operation
Date of operation
Gender and ethnicity
Morphologic type
Fenestration at Fontan
Internal versus external tube
Size of tube graft
Previous cavopulmonary connection
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